Status:
COMPLETED
Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Proliferative Diabetic Retinopathy
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
To determine the vitreous levels of fractalkine, cysteine-rich 61 (Cyr61), and VEGF in patients with PDR. Verifying that it is greater to that found in non-diabetic patients with different non-angioge...
Detailed Description
Introduction: Angiogenesis, the growth and proliferation of new blood vessels, is an important aspect of the vascular proliferation found in tumor growth, wound repair, inflammatory states, and ische...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients with type 1 or type 2 diabetes mellitus
- Not eligible for any currently approved treatments or experimental protocols
- Patients with PDR who receiving vitreoretinal surgery.
Exclusion
- A condition that would preclude a patient for participation in the study in opinion of investigator, e.g., unstable medical status including glycemic control and blood pressure
- Panretinal laser photocoagulation in the study eye
- Previous treatment with intravitreal or sub-Tenon triamcinolone
- History of submacular surgery or other surgical intervention for diabetic
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01920984
Start Date
January 1 2005
End Date
December 1 2006
Last Update
August 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, National Taiwan University Hospital
Taipei, Taiwan, 100